

# Umberto Basso

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4825404/umberto-basso-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

8,101  
citations

40  
h-index

87  
g-index

212  
ext. papers

10,447  
ext. citations

4.4  
avg, IF

5.47  
L-index

#	Paper	IF	Citations
200	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1277-1290	59.2	2064
199	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 352-360	59.2	1033
198	Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations <i>Annals of Oncology</i> , <b>2015</b> , 26, 288-300	10.3	424
197	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 829-841	59.2	280
196	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 812-822	21.7	259
195	Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4906-11	2.2	202
194	A prospective study on glioblastoma in the elderly. <i>Cancer</i> , <b>2003</b> , 97, 657-62	6.4	148
193	Treatment of estrogen receptor-positive breast cancer. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 596-604	4.3	142
192	Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 866-71	2.2	128
191	M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5233-43	12.9	110
190	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1608-1616	2.2	108
189	Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4779-86	2.2	101
188	Endocrine therapy of breast cancer. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 513-22	4.3	95
187	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3839-3846	12.9	90
186	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , <b>2016</b> , 7, 54564-54571	3.3	89
185	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. <i>Cancer</i> , <b>2004</b> , 100, 1221-9	6.4	87
184	Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. <i>Bone</i> , <b>2009</b> , 44, 173-5	4.7	85

183	First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1598-604	2.2	83
182	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR wild-type GIST. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 32-9	5.3	74
181	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. <i>Annals of Oncology</i> , <b>2001</b> , 12, 255-7	10.3	68
180	Cancer-induced hypercalcemia. <i>Anticancer Research</i> , <b>2009</b> , 29, 1551-5	2.3	63
179	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , <b>2015</b> , 68, 147-53	10.2	62
178	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 57, 755-61	4	62
177	Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. <i>Critical Reviews in Oncology/Hematology</i> , <b>2008</b> , 66, 163-70	7	53
176	Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. <i>Oncology</i> , <b>2002</b> , 63, 38-41	3.6	51
175	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919890285	5.4	49
174	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2094-100	3.1	48
173	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , <b>2019</b> , 123, 98-105	5.6	48
172	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2584-2591	7.5	46
171	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1286-94	8.7	46
170	Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective Tissue Cancer NETwork (CONTICANET). <i>Annals of Oncology</i> , <b>2013</b> , 24, 1685-91 <sup>10.3</sup>	10.3	46
169	Medical treatment of malignancy-associated hypercalcemia. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 415-24	13	45
168	Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. <i>European Journal of Cancer Care</i> , <b>2004</b> , 13, 424-33	2.4	44
167	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , <b>2015</b> , 193, 41-7	2.5	43
166	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2735-44	3.1	43

165	Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1093-8	10.3	43
164	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. <i>Oncoscience</i> , <b>2014</b> , 1, 49-56	0.8	43
163	Cells and molecules involved in the development of sarcoid granuloma. <i>Journal of Clinical Immunology</i> , <b>1998</b> , 18, 184-92	5.7	42
162	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-HodgkinB lymphomas. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1352-8	10.3	41
161	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. <i>British Journal of Haematology</i> , <b>1999</b> , 106, 662-8	4.5	41
160	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , <b>2009</b> , 18, 106-16	2	39
159	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 1069-77	4.9	38
158	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 975-83	3.6	38
157	Management of primary and advanced breast cancer in older unfit patients (medical treatment). <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 503-8	14.4	37
156	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 391-5	8.1	35
155	Glycosaminoglycan Profiling in PatientsPPlasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2016</b> , 15, 1822-36	10.6	34
154	Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 336-342	10.3	33
153	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , <b>2015</b> , 10, 517-22	5	32
152	Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1276-82	10.3	32
151	Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature. <i>Drugs and Aging</i> , <b>2007</b> , 24, 967-73	4.7	28
150	Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 1298-312	7.5	28
149	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). <i>World Journal of Surgical Oncology</i> , <b>2014</b> , 12, 46	3.4	27
148	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1727-31	10.3	27

147	FNA cytology and frozen section examination in patients with follicular lesions of the thyroid gland. <i>Anticancer Research</i> , <b>2009</b> , 29, 5255-7	2.3	27
146	Malignant hypercalcemia. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 3462-7	4.3	25
145	A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. <i>Neurology</i> , <b>2002</b> , 58, 1759-64	6.5	25
144	Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. <i>Oncology</i> , <b>2015</b> , 88, 273-80	3.6	23
143	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 355-359.e1	3.3	22
142	Rectal cancer neoadjuvant treatment in elderly patients. <i>Anticancer Research</i> , <b>2006</b> , 26, 3913-23	2.3	22
141	Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 194-200	2.2	21
140	Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. <i>Quality of Life Research</i> , <b>2013</b> , 22, 369-78	3.7	21
139	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , <b>2014</b> , 5, 156-63	3.6	21
138	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2967-71	10.3	21
137	Parathyroid cancer: etiology, clinical presentation and treatment. <i>Anticancer Research</i> , <b>2006</b> , 26, 4803-7	2.3	21
136	Pros-IT CNR: an Italian prostate cancer monitoring project. <i>Aging Clinical and Experimental Research</i> , <b>2017</b> , 29, 165-172	4.8	20
135	Non-cytotoxic therapies for malignant gliomas. <i>Journal of Neuro-Oncology</i> , <b>2002</b> , 58, 57-69	4.8	20
134	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>1999</b> , 277, L240-50	5.8	20
133	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , <b>2018</b> , 1, 467-475	6.7	18
132	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 182-9	3.3	18
131	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , <b>2015</b> , 14, 309-16	3	16
130	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e903-e908	3.3	16

129	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , <b>2015</b> , 115, 764-71	5.6	16
128	Vulnerable and frail elderly: an approach to the management of the main tumour types. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 488-93	7.5	16
127	Chemotherapy and targeted agents for elderly women with advanced breast cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2008</b> , 3, 187-201	2.6	16
126	High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. <i>Cancer Investigation</i> , <b>2001</b> , 19, 41-8	2.1	16
125	Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 253	5.3	16
124	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 143, 46-55	7	15
123	Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. <i>Health and Quality of Life Outcomes</i> , <b>2018</b> , 16, 122	3	15
122	Targeted approaches to triple-negative breast cancer: current practice and future directions. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 605-12	4.3	15
121	Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. <i>Annals of Oncology</i> , <b>2007</b> , 18, 58-63	10.3	15
120	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , <b>2020</b> , 6, 146-150	5.1	15
119	Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. <i>Anticancer Research</i> , <b>2008</b> , 28, 1383-8	2.3	15
118	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 48-55	3.3	14
117	Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years). <i>Journal of Geriatric Oncology</i> , <b>2013</b> , 4, 340-5	3.6	14
116	When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients?. <i>Tumori</i> , <b>2007</b> , 93, 491-492	1.7	14
115	Oncological causes of frailty in older cancer patients. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1230-1	7.5	14
114	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , <b>2019</b> , 12,	6.6	14
113	New strategy developments in brain tumor therapy. <i>Current Pharmaceutical Design</i> , <b>2001</b> , 7, 1553-80	3.3	13
112	Is intra-arterial chemotherapy useful in high-grade gliomas?. <i>Expert Review of Anticancer Therapy</i> , <b>2002</b> , 2, 507-19	3.5	12

111	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , <b>2020</b> , 15, 495-501	5	12
110	Soft tissue limb and trunk sarcomas: diagnosis, treatment and follow-up. <i>Anticancer Research</i> , <b>2014</b> , 34, 5251-62	2.3	12
109	Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. <i>Anticancer Research</i> , <b>2015</b> , 35, 543-7	2.3	12
108	Treatment options for early breast cancer in elderly women. <i>Expert Review of Anticancer Therapy</i> , <b>2004</b> , 4, 197-211	3.5	11
107	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , <b>2015</b> , 11, 2881-91	3.6	10
106	Sorafenib is active on lung metastases from synovial sarcoma. <i>Annals of Oncology</i> , <b>2009</b> , 20, 386-7	10.3	10
105	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , <b>2018</b> , 38, 5773-5782	2.3	10
104	Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. <i>Future Oncology</i> , <b>2015</b> , 11, 965-73	3.6	9
103	Cost of illness of urothelial bladder cancer in Italy. <i>ClinicoEconomics and Outcomes Research</i> , <b>2017</b> , 9, 433-442	1.7	9
102	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , <b>2017</b> , 1, 41-47	0.6	9
101	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e161-9	3.3	9
100	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. <i>Journal of Bone and Mineral Metabolism</i> , <b>2012</b> , 30, 461-7	2.9	9
99	Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. <i>Menopause</i> , <b>2010</b> , 17, 524-8	2.5	9
98	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e187-e194	3.3	9
97	International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26. <i>BMC Cancer</i> , <b>2018</b> , 18, 1104	4.8	9
96	Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 401-406	3.6	8
95	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 477-488	3.3	8
94	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 615-20	3.5	8

93	Adjuvant treatment for elderly patients with colon cancer. An observational study. <i>Anticancer Research</i> , <b>2008</b> , 28, 2513-8	2.3	8
92	Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 613-20	4.3	7
91	Determining therapeutic approaches in the elderly with rectal cancer. <i>Drugs and Aging</i> , <b>2007</b> , 24, 781-90	4.7	7
90	Recommendations for the management of malignant gliomas in the elderly. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 643-54	3.5	7
89	Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A case-control study. <i>Biomedicine and Pharmacotherapy</i> , <b>2002</b> , 56, 416-20	7.5	7
88	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , <b>2020</b> , 25, e1509-e1515	5.7	7
87	Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 264-7	2.4	7
86	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 4687-4695	3.9	6
85	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2016</b> , 12, 493-502	3.6	6
84	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 679-85	4.9	6
83	Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases. <i>Anti-Cancer Drugs</i> , <b>2014</b> , 25, 1227-30	2.4	6
82	Changing boundaries in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , <b>2001</b> , 1, 357-70	3.5	6
81	Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With Everolimus. <i>American Journal of Therapeutics</i> , <b>2016</b> , 23, e300-3	1	6
80	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 1115-1123	3.6	5
79	Management of muscle-invasive bladder cancer in the elderly. <i>Expert Review of Anticancer Therapy</i> , <b>2004</b> , 4, 1017-35	3.5	5
78	New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 53-62	3.5	5
77	Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. <i>BMC Cancer</i> , <b>2016</b> , 16, 752	4.8	5
76	Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 290-297	3.6	5



75	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	5
74	Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. <i>Anticancer Research</i> , <b>2011</b> , 31, 693-7	2.3	5
73	Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml. <i>Nuclear Medicine Communications</i> , <b>2018</b> , 39, 260-267	1.6	4
72	A Solitary Metastasis for a Malignant Schwannoma in the Gallbladder Detected by 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2016</b> , 41, 666-7	1.7	4
71	Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 553	5.3	4
70	Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?. <i>European Urology</i> , <b>2014</b> , 66, 179-80	10.2	4
69	Metastatic malignant soft tissue myoepithelioma: a case report showing complete response after locoregional and systemic therapy. <i>Journal of Surgical Case Reports</i> , <b>2013</b> , 2013,	0.6	4
68	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , <b>2011</b> , 73, 78-88	5.9	4
67	Cancer in the elderly. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6 Suppl 1, 115-8	3.7	4
66	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, 137-145.e4	3	4
65	Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. <i>Anticancer Research</i> , <b>2007</b> , 27, 1079-85	2.3	4
64	Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. <i>Clinical Imaging</i> , <b>2017</b> , 43, 110-116	2.7	3
63	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , <b>2016</b> , 12, 909-19	3.6	3
62	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 167-78	3.5	3
61	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5089-5089	2.2	3
60	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4568-4568	2.2	3
59	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5030-5030	2.2	3
58	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , <b>2021</b> , 26, 740-750	5.7	3

57	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 137, 154-164	7	2
56	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi252	10.3	2
55	Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1175, 89-92	6.5	2
54	Do older women with breast cancer benefit from adjuvant chemotherapy?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 652-3		2
53	Controversies in the therapy of low-grade glioma: when and how to treat. <i>Expert Review of Anticancer Therapy</i> , <b>2002</b> , 2, 529-36	3.5	2
52	Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 170, 103579	7	2
51	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 92-92	2.2	2
50	Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4577-4577	2.2	2
49	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14).. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 787835	5.3	2
48	Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. <i>Anti-Cancer Drugs</i> , <b>2021</b> , 32, 222-225	2.4	2
47	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , <b>2020</b> , 6, 65	6.9	2
46	Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 626104	5.3	2
45	To Transplant or Not to Transplant During the SARS-CoV-2 Pandemic? That Is the Question. <i>Oncologist</i> , <b>2021</b> , 26, e336-e337	5.7	2
44	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , <b>2018</b> , 14, 2691-2699	3.6	2
43	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , <b>2021</b> , 16, 625-632	5	2
42	Axillary lymph node metastases detection with 99mTc-sestamibi scintimammography in patients with breast cancer undergoing curative surgery. <i>Anticancer Research</i> , <b>2007</b> , 27, 2949-52	2.3	2
41	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. <i>European Urology Focus</i> , <b>2022</b> ,	5.1	2
40	More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis. <i>Annals of Oncology</i> , <b>2016</b> , 27, 202-3	10.3	1

39	OECI accreditation at Veneto Institute of Oncology IOV -- IRCCS, general framework and multidisciplinary approach. <i>Tumori</i> , <b>2015</b> , 101 Suppl 1, S38-41	1.7	1
38	Temozolomide in Glioblastoma Multiforme of the Elderly. <i>Tumori</i> , <b>2002</b> , 88, S69-S70	1.7	1
37	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 253-253	2.2	1
36	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4570-4570	2.2	1
35	Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e17007-e17007	2.2	1
34	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the PameritPstudy. <i>Japanese Journal of Clinical Oncology</i> , <b>2021</b> , 51, 484-491	2.8	1
33	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells-Cell Interaction. <i>Blood</i> , <b>1999</b> , 93, 1277-1286	2.2	1
32	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 547-547	2.2	1
31	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211021667	1.8	1
30	Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. <i>Anticancer Research</i> , <b>2008</b> , 28, 491-3	2.3	1
29	Association of body surface area with fat mass, free fat mass and total weight in healthy individuals, and implications for the dosage of cytotoxic drugs. <i>Clinical Nutrition ESPEN</i> , <b>2021</b> , 43, 471-477 <sup>3</sup>		0
28	Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus. <i>Anticancer Research</i> , <b>2008</b> , 28, 4095-100	2.3	0
27	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 17588359221079580	5.4	0
26	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.. <i>Anticancer Research</i> , <b>2022</b> , 42, 165-172	2.3	0
25	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 727	3.6	0
24	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. <i>Cancers</i> , <b>2022</b> , 14, 2568	6.6	0
23	Adjuvant! Online or comprehensive geriatric assessment for women over 70 years with primary breast cancer?. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1247	8.7	
22	Nutritional habits and body mass index in the elderly population: can this information be useful before planning chemotherapy administration in older cancer patients?. <i>Nutrition and Cancer</i> , <b>2008</b> , 60, 552-4	2.8	

21	Thyroid C-cell hyperplasia shown by combined In-111 pentetretotide, Tc-99m pertechnetate, and Tc-99m MIBI scintigraphy. <i>Clinical Nuclear Medicine</i> , <b>2007</b> , 32, 378-9	1.7
20	Overprotective Caregivers of Elderly Cancer Patients: A Case Report. <i>Tumori</i> , <b>2006</b> , 92, 362-363	1.7
19	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , <b>2021</b> , 12, 1037-1046	2.5
18	Prognostic and predictive role of CTCs and AR-V7+ CTCs expression in metastatic castrate resistant prostate cancer (mCRPC): A Feasibility study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 367-367	2.2
17	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15588-e15588 <sup>2.2</sup>	2.2
16	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15563-e15563	2.2
15	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 216-216	2.2
14	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 206-206	2.2
13	Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16045-e16045	2.2
12	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15595-e15595 <sup>2.2</sup>	2.2
11	Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 210-210	2.2
10	Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 205-205	2.2
9	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 549-549	2.2
8	Chemotherapy (CT) for advanced soft tissue sarcoma (STS) in older patients (pts): Toxicity and outcomes in a single center experience.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e21527-e21527	2.2
7	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 189-189	2.2
6	Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 90-90	2.2
5	Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 208-208	2.2
4	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 421-421	2.2

- 3 Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. *Journal of Clinical Oncology*, **2014**, 32, 374-374 2.2
- 2 Rectal cancer adjuvant chemotherapy: when is more useful?. *Anticancer Research*, **2008**, 28, 1805-12 2.3
- 1 Role of neoadjuvant treatment in cT3N0M0 rectal cancer. *Anticancer Research*, **2008**, 28, 4129-35 2.3